Avicanna Stock Revenue

AVCNF Stock  USD 0.17  0.02  10.53%   
Avicanna fundamentals help investors to digest information that contributes to Avicanna's financial success or failures. It also enables traders to predict the movement of Avicanna OTC Stock. The fundamental analysis module provides a way to measure Avicanna's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Avicanna otc stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Avicanna OTC Stock Revenue Analysis

Avicanna's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Current Avicanna Revenue

    
  3.27 M  
Most of Avicanna's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avicanna is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Based on the latest financial disclosure, Avicanna reported 3.27 M of revenue. This is 99.96% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 99.97% higher than that of the company.

Avicanna Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avicanna's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Avicanna could also be used in its relative valuation, which is a method of valuing Avicanna by comparing valuation metrics of similar companies.
Avicanna is currently under evaluation in revenue category among its peers.

Avicanna Fundamentals

About Avicanna Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Avicanna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avicanna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avicanna based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Avicanna OTC Stock

Avicanna financial ratios help investors to determine whether Avicanna OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Avicanna with respect to the benefits of owning Avicanna security.